Want to see TNYA full AI Analyst Report?
TNYA Stock Chart & Stats
$0.70
-$0.05(-3.69%)
At close: 4:00 PM EST
$0.70
-$0.05(-3.69%)
Day’s Range― - ―
52-Week Range$0.52 - $2.35
Previous CloseN/A
Volume1.07M
Average Volume (3M)2.50M
Market Cap
$130.12M
Enterprise Value$86.67M
Total Cash (Recent Filing)$78.08M
Total Debt (Recent Filing)$3.95M
Price to Earnings (P/E)―
Beta2.89
Next Earnings
Nov 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding224,230,010
10 Day Avg. Volume3,475,805
30 Day Avg. Volume2,499,076
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue64.92
Enterprise Value/Gross Profit24.62
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$13.00Price Target Upside1757.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$4.00M
Bulls Say, Bears Say
Bulls Say
Multi-modal Cardiovascular PipelineThe use of multiple therapeutic modalities gives Tenaya several approaches to address cardiovascular disease mechanisms and may diversify development opportunities. A pipeline aimed at correcting or modifying underlying causes could support differentiated long-term value if clinical programs demonstrate safety and efficacy.
Conservative LeverageVery low leverage reduces fixed financial obligations and near-term balance-sheet pressure while the company funds clinical development. This provides more flexibility than a heavily indebted structure, although it does not eliminate the need for external capital while programs remain pre-commercial.
New Financial LeadershipA new CFO can improve oversight of cash planning, financing decisions, and capital allocation during an extended clinical-development period. Stronger financial leadership is particularly relevant for a company dependent on disciplined funding of research programs and future partnership opportunities.
Bears Say
Large Ongoing LossesDeep operating and net losses show that Tenaya has not yet converted its development platform into sustainable earnings. Continued losses can require repeated financing or partnerships and make future performance highly dependent on clinical progress and successful commercialization.
Persistent Cash BurnNegative operating and free cash flow indicate that ongoing activities consume substantial cash rather than funding themselves. Although annual operating burn improved from 2022 to 2025, the latest free-cash-flow trend remains unfavorable, limiting financial durability over the next several quarters.
Capital-base ErosionThe sharp reduction in equity reflects the cumulative effect of ongoing losses and weak returns on capital. A smaller capital base reduces financial resilience and increases the importance of future funding, partnerships, or clinical milestones to sustain development without further dilution.
Tenaya Therapeutics News
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $0.52 and its highest was $2.35 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Tenaya Therapeutics’s market cap is $130.12M.
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 30 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.132.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 224,230,010 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went down -7.526%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Currently, no hedge funds are holding shares in TNYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenaya Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (1757.14% Upside)
$13.00 (1757.14% Upside)
Blogger Sentiment
Bullish
TNYA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.28%
12-Months-Change
Fundamentals
Return on Equity
-108.05%
Trailing 12-Months
Asset Growth
-23.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tenaya Therapeutics
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
TNYA Stock 12 Month Forecast
Average Price Target
$13.00
▲(1757.14% Upside)
Technical Analysis
Galectin Therapeutics
―
Abeona Therapeutics
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Candel Therapeutics
―
Ownership Overview
22.65% Insiders
4.44% Mutual Funds
0.43% Other Institutional Investors
68.28% Public Companies and Individual Investors